France and Spain advance Airbus A400M deliveries under new agreement

Bruno Even Chief Executive Officer Airbus Helicopters Airbus SE
Bruno Even Chief Executive Officer Airbus Helicopters - Airbus SE
0Comments

Airbus and OCCAR have finalized an agreement with the A400M launch nations, ensuring the continuation of production and improvements in operational costs for the program. This agreement includes commitments from France and Spain to expedite the delivery of four and three A400M aircraft, respectively.

Airbus has pledged to enhance operational cost efficiency through maintenance optimization and other measures. These efforts aim to speed up future developments of the A400M, bolstering Europe’s defense capabilities and strategic autonomy in air transport.

The agreement stipulates that Airbus and OCCAR will annually review the industrial status of the program. This annual review aims to provide stability for A400M production, support platform evolution, and create export opportunities.

Airbus is exploring new capabilities such as standoff jamming, increasing payload capacity to 40 tonnes, serving as a mothership for remote carriers, and firefighting. These developments are intended to broaden the applications of the A400M, addressing current and future global needs for operators.



Related

Paul Hudson Chief Executive Officer Sanofi SA

Acoziborole receives key EU panel backing as single-dose treatment for sleeping sickness

Acoziborole Winthrop, a new oral treatment for sleeping sickness developed by the Drugs for Neglected Diseases initiative (DNDi) and Sanofi, has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for…

Martin Lundstedt President and CEO at Volvo Group North America LLC Volvo Group North America LLC

Volvo announces updated share and vote count after series conversion

The number of votes in AB Volvo has changed following the conversion of 2,000,619 Series A shares into an equal number of Series B shares.

Paul Hudson Chief Executive Officer Sanofi SA

Sanofi and Regeneron’s Dupixent recommended for EU approval in young children with chronic urticaria

Sanofi and Regeneron have announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Dupixent (dupilumab) for children aged two to 11 years with…

Trending

The Weekly Newsletter

Sign-up for the Weekly Newsletter from EU Business Daily.